This modified Delphi panel confirmed that life-long combination of HBIG and NUCs remains the gold standard for the HBV prophylaxis after LT. Significant variability persists in clinical practice. Prophylactic strategies, especially in low-risk patients, are largely determined on a case-by-case basis, guided by patient characteristics rather than standardized protocols.
Battistella et al. (Sun,) studied this question.